LHNYSEServices-Medical LaboratoriesFiscal year ends December 31
LABCORP HOLDINGS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$318.83+0.88 (+0.28%)
Close on Oct 19, 2026
- Market cap
- $26.14B
- P/E (TTM)
- 26.4
- Dividend yield
- 0.90%
LABCORP HOLDINGS INC. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | $11.16B | $11.01B | $10.88B | $10.73B | $10.52B | $10.29B | $10.14B | $9.90B | $9.70B | $9.51B | $9.42B | $9.35B | 77.8% | +6.1% |
| Biopharma Laboratory Services | $3.21B | $3.16B | $3.10B | $3.07B | $3.01B | $2.93B | $2.92B | – | – | – | – | – | 22.4% | +6.6% |
| Drug Development | – | – | – | – | – | – | – | $2.85B | $2.83B | $2.82B | $2.77B | $2.73B | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | $1.85B | $1.81B | $1.78B | $1.72B | $1.66B | $1.62B | $1.61B | $1.60B | $1.60B | $1.57B | $1.59B | $1.62B | +11.7% |
| Biopharma Laboratory Services | $531.20M | $512.30M | $498.50M | $493.10M | $481.80M | $465.90M | $458.90M | – | – | – | – | – | +10.3% |
| Corporate Segment [Member] | -$457.20M | -$466.40M | -$482.20M | -$570.60M | -$633.20M | -$674.30M | -$670.80M | -$656.10M | -$653.20M | -$650.80M | -$644.10M | -$609.30M | -27.8% |
| Drug Development | – | – | – | – | – | – | – | $437.30M | $425.40M | $422.60M | $396.30M | $382.40M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Labcorp's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.